CVS). Express Scripts' proposal, first made last month, includes $29.25 a share in cash and 0.426 shares for each Caremark share. Express Scripts said its $25 billion deal gives holders a 7% premium to CVS' all-stock offer, which would swap 1.67 CVS shares for each Caremark share. Last week, Caremark formally rejected the Express Scripts proposal. Express Scripts replied by threatening to launch a proxy fight to replace four directors on the Caremark board, though Caremark noted that its merger with CVS is scheduled to close this quarter -- before the company's annual meeting would be held. The spread between the offers, once as wide as 13%, has been narrowing over the last week as Wall Street has taken to betting that CVS will prevail. Caremark has said it believes a CVS merger presents strategic opportunities absent from an Express Scripts tie-up and that the Express Scripts deal could be derailed by antitrust issues. Express Scripts says its offer is superior and that shareholders should have a chance to vote. On Tuesday, Caremark fetched $56.83 -- in line with the $56.87 Express Scripts deal.